Related Experiment Video
Updated: May 15, 2026
09:54
Laboratory Scale Production and Purification of a Therapeutic Antibody
Published on: January 24, 2017
Recombinant Protein Drugs: A 2025 Update
Hèctor López-Laguna1,2,3, Eloi Parladé3,4, Marianna T P Favaro2,3
1Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, 08195, Sant Cugat del Vallès, Spain.
Summary
Recombinant protein therapeutics are evolving into highly engineered, multifunctional platforms. Innovations in production, engineering, and regulation are driving the next generation of advanced biologic drugs.
Area of Science:
- Biotechnology
- Molecular Biology
- Drug Development
Background:
- Recombinant protein therapeutics have advanced from simple replacement drugs to complex, multifunctional platforms.
- Innovations in synthetic biology, host cell engineering, and bioprocess optimization are key drivers of this evolution.
- Next-generation protein formats include bispecific antibodies, nanobodies, and fusion proteins with diverse therapeutic applications.
Purpose of the Study:
- To provide a 2025 update on the field of recombinant protein drugs.
- To integrate recent advances in production platforms, protein engineering, and regulatory science.
- To outline how these technological advancements are shaping the future of biologics.
Main Methods:
- Review of recent literature and industry trends in recombinant protein drug development.
- Analysis of innovations in host systems (microbial, mammalian, plant-based) for protein production.
- Examination of modular protein engineering strategies for novel therapeutic formats.
- Assessment of evolving regulatory frameworks and manufacturing models.
Main Results:
- Significant progress in host systems enabling high-fidelity, scalable, and safe protein production.
- Development of diverse next-generation protein formats with expanded therapeutic potential.
- Adaptation of regulatory pathways for complex and personalized biologics.
- Emergence of decentralized and flexible manufacturing models.
Conclusions:
- Recombinant protein drugs are transitioning into versatile platforms for functional reprogramming.
- Technological advancements across production, engineering, and regulation are accelerating biologic innovation.
- The field is poised for the development of sophisticated biologics targeting a wide range of diseases.
Related Concept Videos
01:09Recombinant DNA
Overview
01:09Recombinant DNA
Overview
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...